Stock listing
Travere Therapeutics, Inc.
Selected listing: 17R · TRADEGATE · EUR · DE
Travere Therapeutics, Inc. (Tradegate:17R), Health Technology. Latest release Oct 2, 2026: Travere to Present New Data Supporting FILSPARI® (sparsentan)…
- Ticker
- Tradegate:17R
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Tradegate
- Currency
- EUR
Latest news from Travere Therapeutics, Inc.
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 2, 2026
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 1, 2026
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
September 23, 2026
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Events
Research Travere Therapeutics, Inc.
Travere Therapeutics, Inc. company profile
View the public company page for Travere Therapeutics, Inc. on 6ix.
Travere Therapeutics, Inc. news
Read company news and market updates connected to Travere Therapeutics, Inc..
Travere Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Travere Therapeutics, Inc..